NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Abalos Therapeutics

Abalos Therapeutics

Private
DusseldorfHealthcare & Life Scienceshttps://abalos-tx.com

Last Round

Grant

Mar 18, 2024

Total Funding Raised

$51.31M

Company Overview

Abalos Therapeutics is a biotechnology company developing a novel anti-cancer approach that uses the unique immune stimulation of the arenavirus to provide the full breadth of the immune system's power specifically against cancer cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

arenavirus immunotherapyimmuno-virotherapynon-oncolytic virotherapycancer immunotherapyimmuno-oncologysolid tumor therapyvirotherapyviral immunotherapyengineered virus therapyviral vectormetastatic cancer treatmentIO therapybiologics developmentdrug discovery platformpreclinical drug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Abalos Therapeutics Comparables

Compare Abalos Therapeutics with similar companies based on industry and business-model similarity.

Abalos Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TILT Biotherapeutics
77%
Candel Therapeutics, Inc.
75%
Replimune Group Inc.
73%

Abalos Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 18, 2024
Series A ExtensionOct 14, 2021
Series AOct 15, 2019

Key People

Founding team and executive leadership

Dethardt Müller

Chief Technology Officer

Executive Team

Abalos Therapeutics Investors

Notable investors and investment history

Abalos Therapeutics investors
InvestorRounds
Boehringer IngelheimSeries A Extension, Series A
NRW.BankSeries A Extension, Series A
Hx Bio VenturesSeries A Extension
Boehringer Ingelheim Venture FundSeries A Extension, Series A
Ventura BioMed InvestorsSeries A Extension
Gründerfonds RuhrSeries A Extension, Series A
High-Tech GründerfondsSeries A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 4, 2025

    Added Ventura BioMed, a biotechnology startup, as a customer.

Abalos Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Abalos Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Abalos Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersDusseldorf
Employee Range22
Year Founded2019
Last FundingMar 18, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.